A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia - Join Clinical Trial NCTNCT05952037
How to Join This Clinical Trial - NCTNCT05952037
Learn how to participate in this PHASE2 trial studying an investigational therapy for Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2 - Safety and effectiveness study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT05952037 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 72 locations. Find a study site near you:
Clinical Research Site
Duarte, California 91010-3012 - United States
Status: RECRUITING
Clinical Research Site
Denver, Colorado 80218 - United States
Status: RECRUITING
Clinical Research Site
Washington D.C., District of Columbia 20007-2113 - United States
Status: COMPLETED
Clinical Research Site
Miami, Florida 33136-2107 - United States
Status: RECRUITING
Clinical Research Site
Warrenville, Illinois 60555-3269 - United States
Status: RECRUITING
Clinical Research Site
Waukee, Iowa 50263 - United States
Status: COMPLETED
Clinical Research Site
Baltimore, Maryland 21201-1544 - United States
Status: COMPLETED
Clinical Research Site
Boston, Massachusetts 02215-5418 - United States
Status: RECRUITING
Clinical Research Site
Rochester, Minnesota 55905-0001 - United States
Status: RECRUITING
Clinical Research Site
Hattiesburg, Mississippi 39401-7233 - United States
Status: COMPLETED
And 62 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE2 clinical trial for Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships